semaj83/ctmatch_classification huggingface dataset:
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Disorders of Sex Development Hypospadias Genital or gonadal abnormalities as evidenced by physical examination or imaging (including but not limited to hypospadias, microphallus, clitoromegaly, ambiguous genitalia), with no cause identified by standard clinical evaluation  Inability to provide informed consent
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Delayed;Development;Physical Delayed; Development, Intellectual clinical diagnosis of motor developmental delay available results of functional assessments at ages older than 18 months Functional measures either GMFM or BSID_II  single domain delay other than motor (e.g., speech delay)
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 3.0-18.0,  Developmental Disability has a developmental disability enrolled in any of the randomly selected special education schools caregivers signed the informed consent  not a student in any of the randomly selected special education schools caregivers refused to participate and sign the informed consent age not in the range of 3 years old
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 12.0-21.0,  Turner Syndrome Turner Syndrome Mosaicism, 45, X/46, XX or XY Turner Syndrome Mosaicism 46,X,I(X)(Q10)/45,X Turner Syndrome Karyotype 46,X With Abnormal Sex Chromosome , Except I(Xq) Female Age 12-21 years XO karyotype in >50% of cells tested with a diagnosis of Turner syndrome (TS) Tanner stage 2-5 for breast development  Growth hormone treatment within the past 3 months Diagnosis of type 1 or type 2 diabetes Untreated hypertension with blood pressure > 99%ile for sex, age and height or >140/90 Weight > 300 lbs Height < 54" Aortic sinus of Valsalva or ascending aorta z-score > 2 Other cognitive, psychiatric, or physical impairment resulting in inability to tolerate the study procedures, including vigorous exercise Pregnancy
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Turner Syndrome Diagnosis of Turner Syndrome  Diagnosis excluding Turner Syndrome
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 12.0-20.0,  Hyperglycemia Type 1 Diabetes Mellitus T1D on insulin pump, no diabetic complication, normal BMI and blood pressure
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 2.0-18.0,  Turner Syndrome Female Bone age <12 years Karyotype: 45, X; 45, X / 46, XXqi; 45, X / 46, XXr; 45, X / 46, XX; 46, XXqi; 46, XXpi; 45, X / 47, XXX; 46, XXp-; 45, X / 46, XXp-; 46, XXq-; 45X / 46, XXq-; 45, X / 46, XX / 47, XXX, etc. (count 50 or more cells) Facial appearance and abnormalities: Patients with at least one of the following signs, which but are not limited to facial pigmented nevus, short neck, webbed neck, low posterior hairline, low-set ears, micrognathia, high-voulted arch, shield-like chest, cubitus valgus, genu valgum, short 4th and 5th metacarpals, nail dysplasia, scoliosis, ptosis and strabismus, cardiovascular abnormalities (such as aortic stenosis, bicuspid aortic valve and hypertension), reproductive abnormalities (such as primary gonadal dysfunction), renal abnormalities, thyroid hypofunction, middle ear lesion, etc Short stature: height below -2.5SD of the mean height of the same age and gender Pre-pubertal (Tanner Stage I ) patients No history of growth hormone treatment The subject and his/her guardian sign the informed consent (if the subject is incapable to sign the informed consent, his/her legal guardian shall sign the name of the subject instead)  Subjects with abnormal liver and kidney functions (ALT > upper limit of normal value; Cr > upper limit of normal value) Subjects positive for anti-HBc, HbsAg or HbeAg in Hepatitis B virus tests Subjects with highly allergic constitution or allergy to proteins or investigational product or its excipient Subjects with systemic chronic disease and immune deficiency Patients diagnosed with tumor For patients whose tumor markers exceeding normal range in combination with other information, considering as potential high risks of tumor, they may be excluded from the treatment Patients with mental disease Subjects with impaired glucose regulation (IGR) (including impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT) ) or diabetes Subjects who took part in other clinical trials within 3 months Subjects who received medicines which may interfere GH secretion or GH function, or other hormones within 3 months (such as sex steroids, glucocorticoids, etc.)
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 3.0-18.0,  Growth Hormone Deficiency Diagnosed as GHD before starting treatment, according to medical history, clinical symptoms and signs, GH provocation tests and imaging and other examinations: 1. According to statistical height data of physical development of Chinese children in nine cities in 2005, the height is lower than 3rd percentile growth curve of the same age, same sex normal children; 2. Height velocity (HV) ≤5.0 cm / yr; 3. GH provocative tests (with two drugs of different mechanism of action) confirmed plasma GH peak <10.0 ng / ml; 4. bone age for girl≤9 years old, for Boy≤10 years old, bone age is one year or more later than the actual age, that is the actual age bone age ≥ 1 year Before puberty (Tanner I stage), age≥3 years old, male or female Have not received hormone therapy within 6 months Subjects is willing and able to cooperate to complete scheduled visits, treatment plans and laboratory tests and other procedures, to sign informed consent  Dysfunction of liver and kidney (ALT> 2 times the upper limit of normal, Cr> upper limit of normal) Patients positive for hepatitis B c-antibody (HBcAb), hepatitis B surface antigen (HBsAg) or hepatitis B e antigen (HBeAg) Patients with known hypersensitivity to PEG Somatropin or Somatropin or any other components of the study product Patients with severe cardiopulmonary or hematological diseases, a current or past history of malignant tumors, immunodeficiency diseases, or mental diseases Potential cancer patients (family history) Patients with diabetics Patients with other growth disorders, such as Turner's syndrome, sexual physical delayed puberty, Laron syndrome, growth hormone receptor deficiency, girls with slowly growing who did not rule out chromosomal abnormalities Patients with congenital bone dysplasia or scoliosis Subjects took part in other clinical trial study during 3 months Other conditions in which the investigator preclude enrollment into the study
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 8.0-15.0,  Hypothyroidism Children with type 1 diabetes aging between 8  Cases with hyperthyroidism . 2. Areas known to have endemic goitre due to nutritional iodine deficiency . 3. History of maternal hypothyroidism and / or congenital hypothyroidism . 4. Children known to be normoglycaemic with already presented thyroid dysfunction . 5. Children with multiple endocrinopathies . 6. Children under treatment with drugs inducing hypothyroidism like amiodarone , lithium . 7. Children under treatment with drugs affecting insulin secretion like steroids , growth hormone therapy
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Developmental Anomalies Patients (children and adults) with development anomalies whose molecular bases are unknown, or for which the pathophysiological mechanism is poorly understood Consent of the patient or his/her legal representative Suitable level of understanding  Patients without national health insurance cover
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 3.0-21.0,  Development; Delayed, Mental Anxiety Situational Anxiety Fear of Other Medical Care Behavior, Coping Behavior Disorders Psychological Disorder Behavior Disorders in Children Patients who meet the following for the ACT Program Patient is diagnosed with a developmental disability and/or behavioral condition Patient has demonstrated inability to cope and cooperate during a healthcare encounter without additional preparation and support Patient scores greater than 7 on the PRAP scale Patient has 1 or more of the commonly seen ACT patient diagnoses listed in the diagnoses list below (additional diagnoses may be added the discretion of the principal investigator) Patients accompanied to the appointment by parents or legal guardian Patients of any gender, race, and ethnicity are potentially eligible for Patients who are scheduled as outpatients or for 23 hour observation Patient is ambulatory (able to walk and can use all 4 extremities for activities of daily living) Diagnoses list Autism Spectrum Disorder, Autism, Autistic  Guardian unable to provide consent Wheel chair bound Prior enrollment in this research study Patients who are scheduled to be admitted (greater than 23 hours) and inpatients Patients who do not meet the ACT Any patient who, in the judgment of the investigators, has insufficient data to complete analysis Adult patients (age 18-21) who have cognitive delays but are their own legal guardian
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 2.0-18.0,  Fertility Preservation Ovarian Tissue Cryopreservation Turner Syndrome Live Birth Premature Ovarian Failure In order to be eligible to participate in this study, a subject must meet all of the following Girls and young females with classic Turner (i.e. 45X monosomy) or Turner variants (e.g. 45X / 46XX mosaicism, ring X mosaicism, isochromosome X) Aged 2 through 18 years who completed the diagnostic work up phase of TS including routine cardiac screening* whose agreement to participate in this study has been signed by the parents (girls 2-11 years old) whose agreement to participate in this study has been signed by the patient and her parents (girls 12-17 years old) whose agreement to participate in this study has been signed by the patient (adolescents of 18 years old)  A potential subject who meets any of the following will be excluded from participation in this study Contra-indications for laparoscopic unilateral oophorectomy under general anaesthesia (e.g. severe cardiovascular comorbidity and/or BMI >40 kg/m2)* Contra-indications for cryopreservation (i.e. active HIV, hepatitis-B or hepatitis-C infection) Based on the international Cincinnati Turner Guideline consensus Meeting, July 2016 and consultation of Dutch cardiologists, paediatric-cardiologists and anaesthesists between 2016-2017 there are no absolute cardiovascular contra-indications for surgical intervention and/or pregnancy. Advice against surgical intervention and/or pregnancy should be based on the patient-specific cardiovascular risk profile. The 2% mortality risk due to acute aortic dissection is based on one survey and literature review study that reported the outcomes of 101 pregnancies in patients with TS after oocyte donation. Only 50% of the patients were screened by a cardiologist before entering the oocyte donation programme. Therefore, all girls who want to participate in this study should have completed the diagnostic work up phase of TS including routine cardiac screening and will be screened by a paediatric anaesthesist. will be based on the patient specific risk profile. See: References
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Sjogren's Syndrome Subjects diagnosed with Sjogren's Syndrome  Subjects previously diagnosed with Sarcoidsis Subjects with positive for Hepatitis B, Hepatitis C, HIV Subjects diagnosed with Cancer within 5 years of screening
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 4.0-12.75,  Attention Deficit Hyperactivity Disorder Problem Behavior Participant must be a child or adolescent between the ages of 4 years, 0 months, and 13 years, 0 months (participants must not be older than 12 years, 11 months). 2. Participant must have a valid diagnosis of attention deficit/hyperactivity disorder (AD/HD). No specification of type (e.g., predominately inattentive type, predominately hyperactive-impulsive type, or combined type) will be necessary. 3. Participant must exhibit disruptive behavior, defined as one or more of the following: 1. physical or verbal aggression towards others: Hitting, kicking, biting, scratching, choking, spitting at, or throwing items at another person, and/or making insults, threats, or swearing at another person. 2. self-injury: Hitting self, biting self, banging head on an object/hard surface, pinching self, or scratching self with visual skin damage. 3. destruction: Damaging (or attempts to damage) personal or public property (e.g., breaking an object into two or more pieces, using an object to break other objects, ripping objects or parts of objects from walls, floors, or furniture, and denting cars, objects, or walls.) 4. noncompliance:Regular occurrence of verbal refusal (e.g., saying "no", "I don't want to", "I won't do it" or "not now") to any academic or non-academic request, and/or any response that does not match the delivered instruction within 30 seconds from the time the instruction was delivered. 5. tantrum:Crying (i.e., any vocalizations [sounds or words] accompanied by facial contraction with and without tears for any period of time) and/or screaming (occurrence of vocalizations above normal conversational volume for any period of time), with or without body flailing. 6. an active diagnosis of disruptive behavior disorder or oppositional defiant disorder. 4. Participant must already be prescribed a stimulant medication for the treatment of AD/HD symptoms and at an approved dose for age  a diagnosis of autism, conduct disorder, or intellectual disability in the moderate, severe or profound range. 2. prescribed or taking a stimulant dosage outside of recommended therapeutic range
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Aortopathies Thoracic Aortic Aneurysm Aortic Valve Disease Thoracic Aortic Disease Thoracic Aortic Dissection Thoracic Aortic Rupture Ascending Aortic Disease Descending Aortic Disease Ascending Aortic Aneurysm Descending Aortic Aneurysm Marfan Syndrome Loeys-Dietz Syndrome Ehlers-Danlos Syndrome Shprintzen-Goldberg Syndrome Turner Syndrome PHACE Syndrome Autosomal Recessive Cutis Laxa Congenital Contractural Arachnodactyly Arterial Tortuosity Syndrome Open to external enrollment Subjects with a genetic diagnosis of Marfan Syndrome (MDS), Loeys-Dietz Syndrome (LDS), or Vascular Ehlers-Danlos Syndrome (EDS); (Positive genetic testing or a previous cardiac study required to be eligible) Family members of eligible subjects (Only family members of subjects with syndromic diagnoses are eligible for external enrollment at this time) Closed to external enrollment Subjects with aortic disease including TAA* or dissection, aortic tortuosity, or aortic hypoplasia/stenosis (based on any cardiac imaging modality including echocardiography, CT, MRI, or angiography) Subjects with aortic valve disease (bicuspid, unicuspid, or tricuspid disease) Control subjects having tissue removed during a surgical procedure (e.g. coronary artery bypass graft surgery (CABG), cardiac transplant, etc.)  • Inability or unwillingness to provide consent (assent when indicated)